Allos Therapeutics to Report 2008 Results on March 3, 2009
27 2월 2009 - 6:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer, today announced that
Paul L. Berns, President and Chief Executive Officer, and members
of Allos' senior management team will provide a company update and
review 2008 results via webcast and conference call on Tuesday,
March 3, 2009, at 4:15 p.m. ET.
The webcast of this call will be available from the homepage and
the investors/media section of the Company's web site,
www.allos.com. Alternatively, callers may participate in the
conference call by dialing 800-762-8795 (domestic) or 480-248-5085
(international). Participants should reference the Allos
Therapeutics conference call. Webcast and telephone replays of the
conference call will be available approximately two hours after the
completion of the call through Friday, March 13, 2009. To access
the replay, callers should dial 800-406-7325 (domestic) or
303-590-3030 (international) and use passcode 3992548#.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on
developing and commercializing innovative small molecule drugs for
the treatment of cancer. In February 2009, the Company announced
the final results from PROPEL, the Company�s pivotal Phase 2 trial
of pralatrexate in patients with relapsed or refractory peripheral
T-cell lymphoma (PTCL). The PROPEL trial was conducted under an
agreement reached with the U.S. Food and Drug Administration under
its special protocol assessment (SPA) process. Based on the results
of the PROPEL trial, the Company intends to submit a New Drug
Application to the U.S. Food and Drug Administration for
pralatrexate for the treatment of relapsed or refractory PTCL in
the first half of 2009. The Company is also investigating
pralatrexate in patients with non-small cell lung cancer, bladder
cancer and a range of lymphoma sub-types. The Company currently
retains exclusive worldwide rights to pralatrexate for all
indications. For additional information, please visit the Company�s
website at www.allos.com.
Safe Harbor Statement
The 2008 results press release and conference call will contain
forward-looking statements that involve significant risks and
uncertainties, including those contained in the "Risk Factors"
section of the company's Form 10-Q for the quarter ended September
30, 2008 and in the company's other periodic reports and filings
with the Securities and Exchange Commission. Allos is providing the
information contained in the press release and conference call as
of the date of the release and does not undertake any obligation to
update any forward-looking statements as a result of new
information, future events or otherwise. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call.
No forward-looking statement can be guaranteed and actual events
and results may differ materially from those projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics, Inc. News Articles